CONTROLLING INFLAMMATION

SVB Leerink Global Healthcare Conference 2020
This presentation has been prepared by InflaRx N.V. ("InflaRx"), a US-Nasdaq publicly listed Dutch company having its principle place of business in Germany. This presentation is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and neither the delivery of this presentation at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof.

This presentation may contain forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. All statements other than statements of historical facts contained in this presentation, including statements regarding future results of operations and financial position, business strategy, current and prospective product candidates, planned clinical trials and preclinical activities, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, expectations regarding market acceptance and size, plans and objectives of management for future operations, and future results of anticipated product candidates, are forward-looking statements. These risks and uncertainties include those described under the caption “Risk Factors” in InflaRx's Registration Statement on Form F-1 and the accompanying prospectus filed with the Securities and Exchange Commission in connection with the company’s initial public offering and other filings with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and InflaRx’s own internal estimates and research. While InflaRx believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.
Investment Highlights

**LEADING PROPRIETARY ANTI-C5A TECHNOLOGY**

- Complete and selective blockade of the biological activity of C5a in vitro and in vivo
- Strong patent coverage on anti-C5a technology until end of 2030 / 2035 with extension

**ESTABLISHED CLINICAL EFFICACY FOR LEAD DRUG IFX-1**

- Proven anti-inflammatory effect in multiple Phase II studies
- Statistically significant reduction of inflammatory lesions in Phase IIb Hidradenitis Suppurativa study and impressive long-term efficacy
- Full data set analysis warrants continued development towards Phase III despite missing the primary endpoint (HiSCR) in Phase IIb study
- Favorable safety profile and excellent tolerability (n > 300 patients)

**MULTIPLE ONGOING STUDIES AND INDICATION + PIPELINE EXTENSION**

- Ongoing Phase IIb studies in ANCA-associated vasculitis in the US and EU
- Ongoing Phase IIa open label study in Pyoderma Gangraenosum in US and Canada
- Follow-on anti-C5a mAb IFX-2 in pipeline (pre-clinical stage)
- Pipeline extension of IFX-1 in other inflammatory diseases & oncology
Pipeline with Multiple Opportunities

We have multiple ongoing Phase II studies with potential to expand into further indications

<table>
<thead>
<tr>
<th>PROPOSED INDICATIONS</th>
<th>PREVALENCE</th>
<th>PRE-CLINICAL</th>
<th>PHASE I</th>
<th>PHASE II</th>
<th>PHASE III</th>
<th>UPDATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>IFX-1 C5a Inhibitor</td>
<td>Hidradenitis Suppurativa (HS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase IIb completed</td>
</tr>
<tr>
<td></td>
<td>• Up to 200,000 patients in the US</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Planning for next steps</td>
</tr>
<tr>
<td></td>
<td>• Over 200,000 patients in Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ANCA-Associated Vasculitis</td>
<td>• ~40,000 patients in the US</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase IIb enrollment ongoing in both Europe and US</td>
</tr>
<tr>
<td></td>
<td>• ~75,000 patients in Europe</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pyoderma Gangraenosum</td>
<td>• ~50,000 patients in the US and Europe are affected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Phase IIa open label enrollment ongoing in US and Canada</td>
</tr>
<tr>
<td>Oncology</td>
<td>• Undisclosed Indication</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Development of TPP ongoing</td>
</tr>
<tr>
<td>IFX-2 C5a Inhibitor</td>
<td>Undisclosed Chronic Inflammatory and Autoimmune Diseases</td>
<td>• Not applicable</td>
<td></td>
<td></td>
<td></td>
<td>• Developing as injectable with optimized use for other chronic inflammatory indications</td>
</tr>
</tbody>
</table>

These compounds and/or uses of approved products are investigational and have not been approved by the FDA or any other regulatory agency for the uses under investigation. The safety and efficacy of these agents have not been established.
The Terminal Complement Pathway

C5 concentration in blood: ~75 µg/ml (~400 nM)

C5a concentration in blood: 10 ~ 30 ng/ml (~1-2.5 nM)

Membrane Attack Complex (MAC) triggers lysis of pathogens

C5b-9 = MAC

C5aR

❖ cell activation
❖ cytokine generation

C5L2

❖ PKC-signaling
❖ HMGB-1 induction* (Inflammasome)

C5L2 has a different binding pocket for C5a compared to other ligands like C3a, ASP, etc. and this causes different cell signaling.*

The C5a signaling has been shown to be pro-inflammatory.**

Inflammation

Calant D. et. al. J. Biol. Chem. 2003, 278 (13) 11123–11129

Colley et al. MABS. 2018,10 (1), 104
Songlin et. al. J. Biol. Chem. 2019; 294(21) 8384–839
Muenstermann et al.. Virulence, 2020; 10(1) 677-694
**Main Goals**

- Test a dose-dependent effect of IFX-1 on HiSCR response at week 16 (primary endpoint)
- Assess long-term safety of IFX-1
- Test durability of response with lower maintenance therapy in open label extension period

**Important Note:** Patients entering the OLE were not unblinded to their initial therapy
SHINE Study: Primary Outcome HiSCR at Week 16 versus AN Count Reduction

HiSCR response rate (%) week 16*

- Placebo: 47.1%
- Minimum: 40.0%
- Low: 51.5%
- Medium: 38.7%
- High: 45.5%

$n = \approx 35/\text{group}$

AN count score change (mean %) week 16*

- Placebo: -26.5%
- Minimum: -32.7%
- Low: -54.6%
- Medium: -44.9%
- High: -47.7%

Treatment groups: placebo, minimum, low, medium, high

Primary endpoint: HiSCR dose response signal not met but signal towards improved AN count

* Full analysis set
SHINE Study:
Outcome on Draining Fistula and IHS-4 Score Reduction – Week 16

**Draining fistula change (mean %)**

- Placebo: -18
- Minimum: -14.5
- Low: -15
- Medium: -28
- High: -63.2

**IHS-4 score change (mean %)**

- Placebo: -19.8
- Minimum: -24.6
- Low: -41.1
- Medium: -38.4
- High: -51.5

Statistically significant change in DF and in IHS-4 scores detected

*Full analysis set for patients with at least 1 DF at baseline, baseline adjusted**

**Full analysis set – baseline adjusted**
Comparison of HiSCR for Week 16 Responder versus Non-responder Groups (OLE) Over Time

HiSCR response rate (%) per visit* (OLE) – with 95% CI

Responders: 71% maintain HiSCR response with low dose IFX-1
Non-responders: 42% become HiSCR responders with medium dose IFX-1

* Full analysis set
Inflammatory Lesion Reductions in All OLE Patients at End of Treatment (Week 40) Compared to Placebo Group Performance in Main Period (Week 16)

Marked improvement of all inflammatory lesions over time – not explainable by placebo effect

* Full analysis set (unadjusted)
## OUR CONCLUSIONS

- HiSCR is burdened by high variability (driven by AN count variability) and by a lack of capturing reduction of draining fistula
- Evidence for a high C5a turnover rate in HS, leading to increased dose requirements of IFX-1
- IFX-1 leads to a marked reduction of all inflammatory lesions in HS with a durable long-term effect detected even at non-optimal doses
- IFX-1 long-term treatment was well tolerated, no drug related SAEs* in the open label extension phase

## NEXT STEPS

- Request End-of-Phase II FDA Meeting in Q1 2020
- Discuss with FDA the path forward for regulatory approval towards a Phase III pivotal program
- Depending on meeting timing and feedback: define path forward by 2H 2020

* Serious adverse events
Pyoderma Gangraenosum (PG)

AN AUTOIMMUNE CONDITION WITH HIGH UNMET NEED

CLINICAL FEATURES

• PG is a rare ulcerative skin disorder that can lead to chronic painful and difficult-to-treat wounds / ulcers occurring predominantly in people in their 40s and 50s
• Many PG patients also suffer from other autoimmune disorders, including inflammatory bowel diseases like ulcerative colitis, rheumatoid arthritis, and hematological diseases
• Patients suffer from severe pain, long healing times, and frequent relapses
• Diagnosis is based on the exclusion of other conditions and typical ulcers

INCIDENCE

• Rare - Estimated that up to 50,000 patients in the US and Europe are affected
• Orphan drug market

CURRENT TREATMENT – MEDICAL NEED

• No drugs currently approved in the US or EU
• Current treatment options include the use of systemic immunosuppression in rapidly progressing cases or, for less severe cases, topical or intralesional treatments can be used, including topical steroids
Overview of IFX-1 Phase IIa Study in PG - Study Design

**STUDY OBJECTIVE**

- Assessing safety and efficacy of IFX-1 in PG

  - **Rationale:**
    PG is associated with a neutrophilic leukocytosis, which is likely to be triggered by C5a. Pyoderma Gangraenosum lesions have pronounced neutrophilic infiltration and the expression of interleukin (IL)-1β, IL-17, tumor necrosis factor (TNF)-alpha, and their receptors are significantly elevated, indicating auto-inflammatory conditions.

- **Primary endpoint:**
  Safety

- **Key secondary endpoints:**
  Responder rate defined as Physicians Global Assessment ≤3 of target ulcer at visits V4, V6, V10, and V16 (end of treatment); Time to complete closure of Pyoderma Gangraenosum target ulcer (investigator assessment)

**STUDY DESIGN**

- Open label
- Multi-center in US and Canada
- Target enrollment – **18 patients**
- First patient dosed – June 2019

**TREATMENTS**

- Trial started with 1 dose group: amendment approved to introduce a dose escalation to test 3 dose groups
- Subjects receive IFX-1 dosing every other week
- Dose: 800 mg biweekly first 5 patients
5 patients have been treated

2 out of the first 5 patients showed complete closure of the target ulcer with one patient in full disease remission and second in almost complete disease remission

In one additional patient, initial wound healing activity was detected in the first 2-3 weeks of treatment – but no wound size decrease or closure detected

2 additional patients with extensive disease (very large ulceration / ulcer reaching the entire circumference of the leg) did not heal the target ulcer and are still under treatment

The “responders” have higher baseline C5a levels

PD analysis (C5a levels) warrants higher dosing

Dose escalation recently approved by relevant authorities
Pyoderma Gangreaeosum (PG)

*Two patients show complete wound closure with IFX-1 treatment*

**PATIENT EXAMPLE 1**

- Female patient with extensive genital PG disease and target ulcer on lower extremity
- Various failed treatment attempts including high dose corticosteroids, etc.
- Significantly elevated baseline C5a levels
- Patient completely healed of all PG lesions and off drug now for 2 months

**PATIENT EXAMPLE 2**

- Male patient with treatment resistant PG disease and Addison’s disease from high-dose GC
- Significantly elevated baseline C5a levels
- Target ulcer is completely healed, and the patient is still on treatment (still one other lesion with minimal opening at different body location)
Our Strategy

GOALS AND STRATEGY

• **Advance** our lead program IFX-1 for HS towards Phase III / approval based on regulatory guidance

• Explore application of IFX-1 for AAV, PG and within the oncology field in Phase II clinical development

• Extend pipeline with initiation of **clinical development of IFX-1** in other complement-mediated autoimmune / inflammatory diseases

• Pursue the **development of IFX-2** and continue to expand the breadth of our anti-C5a technology

• **Continue to explore broadening the R&D pipeline beyond** anti-C5a technology as part of diversification strategy

—we have a strong cash balance to pursue these activities (End of Q3 2019: ~US$151 million)
INFLARX N.V.
Winzerlaer Str. 2
07745 Jena, Germany
Email: info@inflarx.com
Tel: +49-3641-508180
Fax: +49-3641-508181
www.inflarx.com

INVESTOR RELATIONS INFLARX N.V.
Jordan Zwick
Global Head of Business Development & Corporate Strategy
Email: jordan.zwick@inflarx.de